How Does Cibinqo Work? Mechanism of Action Explained in Plain English

Cibinqo (abrocitinib) is described as a "JAK1 inhibitor" — but what does that actually mean? Understanding how this medication works can help you feel more confident about your treatment plan and have better conversations with your doctor. This guide explains the science of Cibinqo in plain, accessible language.

First: What Causes Atopic Dermatitis?

Atopic dermatitis (AD) is not just dry skin — it's a complex, chronic inflammatory disease driven by an overactive immune system. In people with AD, the immune system mistakenly ramps up an inflammatory response in the skin. This triggers the release of chemical messengers called cytokines — particularly IL-4, IL-13, IL-31, IL-22, and TSLP — that cause the hallmark symptoms of eczema:

Intense itching (pruritus)

Dry, flaky, cracked, and inflamed skin

Skin barrier dysfunction that makes the skin leaky and more susceptible to infections

Cytokines are like alarm signals — in AD, the alarm is stuck in the "on" position. Treatment aims to turn down that alarm.

What Is JAK1 and Why Does It Matter?

The cytokines that drive AD don't act directly on skin cells — they deliver their inflammatory messages through a relay system inside the cell called the JAK-STAT pathway. Here's how it works, step by step:

An inflammatory cytokine (like IL-4 or IL-31) attaches to a receptor on the surface of a skin cell.

This activates JAK (Janus kinase) proteins inside the cell — specifically JAK1 for many AD-related cytokines.

JAK1 passes the signal deeper into the cell, activating STAT proteins.

STAT proteins travel to the nucleus and switch on genes that produce more inflammation.

JAK1 is the critical bottleneck in this signaling chain for many of the cytokines involved in AD. By blocking JAK1, Cibinqo interrupts the entire downstream inflammatory cascade.

How Cibinqo Blocks JAK1

Cibinqo (abrocitinib) works by physically blocking the part of the JAK1 enzyme where it gets activated — specifically the adenosine triphosphate (ATP) binding site. Think of it like putting a key in a lock to prevent the lock from opening. When Cibinqo occupies that binding site, JAK1 can't be activated, and the inflammatory signal chain is interrupted.

What makes Cibinqo stand out is its selectivity. In laboratory testing, abrocitinib is:

28-fold more selective for JAK1 over JAK2

>340-fold more selective for JAK1 over JAK3

43-fold more selective for JAK1 over TYK2

This selectivity is thought to reduce off-target effects compared to earlier, non-selective JAK inhibitors. By focusing on JAK1, Cibinqo targets the specific pathway most responsible for AD inflammation while limiting interference with other immune processes.

Which Cytokines Does Cibinqo Block?

By inhibiting JAK1, Cibinqo disrupts the signaling of multiple inflammatory cytokines that are elevated in atopic dermatitis:

IL-4 and IL-13: key drivers of type 2 inflammation and skin barrier dysfunction in AD

IL-31: the "itch cytokine" — blocking IL-31 signaling is why patients often notice rapid relief from itching, sometimes within 2 weeks

IL-22: involved in skin barrier disruption and epidermal abnormalities

TSLP (thymic stromal lymphopoietin): a master regulator that activates the whole type 2 inflammatory response in AD

37,512+ patients found their medications in stock

37K+

Find Cibinqo In Stock Today →

How Is Cibinqo Different From Dupixent?

Dupixent (dupilumab) is a biologic — an injectable antibody that targets the IL-4 receptor on the outside of cells, blocking IL-4 and IL-13 signaling. Cibinqo works inside the cell to block the JAK1 enzyme that IL-4, IL-13, IL-31, IL-22, and TSLP all depend on.

Think of it this way: Dupixent blocks one specific messenger from knocking on the door. Cibinqo blocks the phone inside the house from being answered at all — for multiple messengers at once. This broader intracellular action is why Cibinqo may work for some patients who don't respond to Dupixent, and vice versa.

What Happens When You Stop Cibinqo?

Cibinqo's JAK1 inhibition is reversible. When you stop taking Cibinqo, the drug leaves your system relatively quickly (it has a short half-life of about 3–5 hours for the parent compound). The inflammatory markers it suppresses — including hsCRP, IL-31, and TARC — return to near-baseline within 4 weeks of stopping the medication. This means atopic dermatitis symptoms are likely to return after discontinuation.

Want more background? Read our comprehensive guide on what Cibinqo is used for and how it's dosed.

Skip the calls, skip the stress.

Find Cibinqo In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Finding Cibinqo at a Pharmacy

Cibinqo is only available through specialty pharmacies, which can make it tricky to fill. medfinder calls pharmacies near you to find which ones have your dose in stock, then texts you results — saving you the runaround.